The answer to this question used to be a flat no. Now it’s complicated — in the best way. Medicare has three distinct ways to cover Zepbound in 2026, and which one applies to you depends entirely on why your doctor prescribed it. Get the wrong answer from a quick search and you might show up at the pharmacy expecting coverage that isn’t there, or walk away from $50-per-month access you actually qualify for. This guide separates all three pathways, explains the diagnosis requirements, and walks through the cost numbers you’ll actually see at the counter.
Key Questions, Answered Directly
When we reviewed the most common questions people ask about Zepbound and Medicare, three distinct situations kept coming up. These answers address each one honestly — including the situations where coverage still doesn’t exist.
Yes — but the coverage depends entirely on why it’s being prescribed. Medicare does not cover Zepbound for weight loss under standard Part D rules; that exclusion is written into federal law. However, two exceptions now exist. First, Medicare Part D can cover Zepbound when it’s prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — an FDA indication Zepbound received in December 2024. Second, the Medicare GLP-1 Bridge program, launched July 1, allows eligible Part D enrollees to access Zepbound KwikPen for weight management at a flat $50 per month. If neither of these situations applies to you — if you want Zepbound solely for weight loss and don’t qualify for the Bridge — Medicare won’t cover it.
Zepbound comes in two formats: the KwikPen (a reusable, multi-dose pen that holds four weekly doses) and the single-dose vial and single-dose pen. The Medicare GLP-1 Bridge program covers only the Zepbound KwikPen — not the single-dose vial and not the single-dose pen. This is a CMS-specified restriction in the official program documentation. For the sleep apnea pathway through standard Part D, the formulation restriction may vary by plan — check your specific plan’s formulary. If your doctor writes a Zepbound prescription and it specifies a single-dose vial or pen, the Bridge will not cover it. When asking your doctor for a Bridge-eligible prescription, specify the KwikPen formulation explicitly.
Not under standard Part D rules — the 2003 law that created Medicare Part D explicitly prohibits covering drugs prescribed solely for weight loss. However, the GLP-1 Bridge changes this for many beneficiaries. If you have a BMI of 35 or higher, OR a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease, OR a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease — you likely qualify for the Bridge and can access Zepbound KwikPen for $50 per month. One critical caveat: if you already receive Zepbound through Part D for sleep apnea or diabetes-related conditions, you are not eligible for the Bridge — you continue through your existing Part D coverage.
Zepbound and Mounjaro contain the identical active ingredient — tirzepatide — at the same dosage range. The only difference is the FDA-approved indication on the label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management and obstructive sleep apnea. For Medicare, this brand distinction is everything. Medicare Part D covers Mounjaro for type 2 diabetes under standard Part D rules. Medicare does not cover Zepbound for weight loss alone under standard Part D — even though they are the same molecule. If you have type 2 diabetes and your doctor wants to prescribe tirzepatide, getting it as Mounjaro is the route that uses standard Part D coverage. Zepbound enters the picture for sleep apnea or the Bridge program.
No — and this is the most important financial detail to understand before enrolling. The Medicare GLP-1 Bridge operates entirely outside the standard Part D benefit structure. The $50 copay you pay each month is a separate cost that does not count toward your Part D deductible and does not count toward the $2,100 annual out-of-pocket maximum. This means if you’re also taking other expensive medications covered under standard Part D, those costs continue toward your cap independent of what you pay through the Bridge. Additionally, Extra Help (Low Income Subsidy) does not reduce the $50 Bridge copay — people who normally pay $5 or $10 per drug through Extra Help still pay $50 for Bridge drugs.
In our review of Part D plan requirements for Zepbound OSA coverage, prior authorization is required by virtually every plan. Your doctor must document: a confirmed diagnosis of moderate-to-severe obstructive sleep apnea (ICD-10 code G47.33), a BMI of 30 or higher (the FDA approval applies to adults with obesity), and typically evidence of a sleep study (polysomnography results showing an apnea-hypopnea index of 15 events per hour or higher, which defines moderate-to-severe OSA). Some plans also require documentation of current or attempted PAP therapy (CPAP or BiPAP). If you’ve never had a formal sleep study, your doctor will likely need to order one before the prior authorization can be submitted — this can add four to six weeks to the approval timeline.
The Bridge runs through December 31, 2027. CMS has described it as a bridge to a longer-term coverage model called the BALANCE Model, but implementation of the BALANCE Model has been indefinitely delayed. As of now, there is no confirmed permanent coverage program ready to replace the Bridge when it ends. CMS is expected to report findings from the Bridge demonstration to Congress, which could lead to legislative action to extend or make permanent coverage — but that is not guaranteed. People who start Zepbound for weight loss through the Bridge should understand this is a time-limited program. Most clinical studies show that people who stop GLP-1 medications for weight loss regain a significant portion of the weight they lost, which makes continuity of coverage an important planning consideration.
Medicare Advantage plans (Part C) that include drug coverage follow the same fundamental federal rules as standard Part D — they cannot cover Zepbound for weight loss alone under their normal benefit, and they can cover it for sleep apnea. Most Medicare Advantage plans with drug coverage (MA-PD plans) also participate in the GLP-1 Bridge program alongside standard Part D plans. However, individual MA plan formularies vary more than standard Part D formularies, and some plans dropped Zepbound from their formularies in 2025 before adding it back. Always check your specific MA plan’s current formulary rather than assuming coverage based on what another MA plan does. The Annual Election Period (October 15 through December 7) is your opportunity to switch to a plan with better Zepbound coverage if your current one doesn’t cover it.
Three Ways Medicare Can Cover Zepbound
These are not three versions of the same coverage — they are separate programs with different eligibility rules, cost structures, and time limits. Which one applies to you determines what you pay and whether the costs count toward your annual cap.
When we looked at real coverage denial patterns for Zepbound under Medicare, coding errors were the most preventable cause of rejected claims. The sleep apnea pathway requires ICD-10 code G47.33 (obstructive sleep apnea in adults). If your doctor submits a prior authorization with E66 (obesity) or a weight-management code as the primary diagnosis, the standard Part D claim is legally required to be denied — even if you genuinely have sleep apnea. Before your doctor submits a prior authorization for Zepbound under the OSA pathway, confirm they are using G47.33 as the primary ICD-10 code. Similarly, if you are applying for Bridge coverage for weight management, the Bridge operates on a separate CMS prior authorization track entirely — not through your Part D plan’s normal PA process.
Medicare Coverage for Zepbound + Sleep Apnea
This is the oldest of the three coverage pathways and the most financially advantageous — costs apply toward the annual cap. It opened when the FDA approved Zepbound for obstructive sleep apnea in December 2024, the first-ever medication approved to treat OSA directly.
To access Zepbound through standard Medicare Part D under the sleep apnea indication, you must have: (1) a confirmed diagnosis of moderate-to-severe obstructive sleep apnea — typically defined as an apnea-hypopnea index of 15 or more events per hour on a sleep study, and (2) obesity — the FDA approval requires obesity (BMI 30 or higher) as a co-condition. The prescription must be for the sleep apnea indication specifically, not for weight loss. Most plans also want documentation of current or attempted PAP therapy, or a clinical note explaining why PAP is not appropriate for you. Your plan may cover Zepbound for OSA even if you’ve never tried a CPAP machine, particularly if documented intolerance — but the prior authorization must address this explicitly.
When Zepbound is covered for OSA under standard Part D, your costs follow the normal Part D benefit structure. During the deductible phase, you pay the plan-negotiated price until you meet your annual deductible (up to $615). Once past the deductible, you pay the plan’s tier copay or coinsurance — typically 25% to 33% coinsurance on a specialty tier, which on a drug with an $867 average Part D payment per claim can translate to $200 to $400 per month in initial coverage. Here is the meaningful protection: once your total covered Part D drug spending reaches $2,100, you pay $0 for covered drugs for the rest of the year. For people on other expensive medications as well, this cap can be reached by spring — after which Zepbound costs nothing through December. People on Extra Help (Low Income Subsidy) pay reduced flat copays.
A formal sleep study is the gate that nearly everyone has to pass through for this coverage pathway. If you’ve never been tested for sleep apnea, the process typically starts with a referral to a sleep medicine specialist or pulmonologist. A home sleep apnea test (HSAT) is often the first step — it’s less expensive than an in-lab polysomnography and is covered by Medicare Part B under most diagnostic protocols. If the HSAT shows moderate-to-severe OSA, you have the documentation needed for Zepbound prior authorization. Starting this process now matters if you want to access the OSA coverage pathway — between the referral, the sleep test scheduling, the results review, and the prior authorization submission, plan for four to eight weeks from your first conversation with your doctor to your first Zepbound prescription under this path.
The Medicare GLP-1 Bridge — $50/Month for Weight Management
This program is the most significant expansion of Medicare drug coverage for weight loss in the program’s history — and it runs on a completely separate track from your regular Part D plan. Understanding how it works differently from standard Part D coverage prevents the most common enrollment mistakes.
The Medicare GLP-1 Bridge is a CMS demonstration program that launched July 1 and runs through December 31, 2027. It covers Zepbound KwikPen, Wegovy (injection and tablets), and Foundayo at a flat $50 monthly copay for eligible Part D enrollees. The program does not go through your individual Part D plan — CMS set up a central processing system run by Humana to handle all prior authorizations, claims, and pharmacy payments. Your Part D plan is not involved. Your plan does not need to “opt in.” Any pharmacy that accepts Medicare prescriptions can dispense Bridge medications. Critically: only the Zepbound KwikPen qualifies — the single-dose vial and single-dose pen are not covered by the Bridge. If your doctor writes a prescription for a non-KwikPen formulation, it will not be filled under Bridge pricing.
CMS set clear BMI-based thresholds. Eligibility is assessed at the time GLP-1 therapy was first started — so if your BMI has fallen since you began treatment, you may still qualify based on your starting BMI. People already receiving a GLP-1 through standard Part D for type 2 diabetes, sleep apnea, or cardiovascular risk reduction are not eligible for the Bridge; they continue through their existing Part D coverage.
Tier 1 — BMI 35 or higher: Qualifies without any additional health condition.
Tier 2 — BMI 30 or higher with: heart failure with preserved ejection fraction, uncontrolled hypertension (blood pressure above 140/90 despite two medications), or chronic kidney disease stage 3a or higher.
Tier 3 — BMI 27 or higher with: prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
The $50 Bridge copay is fixed — it does not change based on the coverage phase you’re in, and it does not vary by income. There are two financial consequences that surprise people after enrollment: First, the $50 monthly copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. This is additional spending on top of your Part D costs, not a substitute for them. Second, Extra Help (Low Income Subsidy) subsidies — which normally let low-income beneficiaries pay $5 or $10 per drug — do not apply to Bridge copays. If you’re a dual-eligible beneficiary or receive Extra Help and normally pay very low drug copays, the $50 Bridge copay represents a real and meaningful expense that your subsidies won’t offset. For people with significant other Part D drug costs who expect to hit the $2,100 cap, the OSA pathway (if you qualify) may be financially superior because those costs count toward the cap.
Your first step is asking your doctor whether you meet the BMI and health condition criteria. If you do, your doctor submits the prescription and a prior authorization request directly to the CMS central processor (not your Part D plan). Once approved, you go to any participating pharmacy and pay $50 for a one-month supply of Zepbound KwikPen. Subsequent monthly fills do not require new prior authorization unless you switch to a different covered medication. Your doctor does not need to be enrolled as a Medicare provider to prescribe or submit a prior authorization for the Bridge. The best starting point is asking your doctor: “Do I qualify for the Medicare GLP-1 Bridge, and can you check my BMI eligibility from when I first started any GLP-1 medication?”
Zepbound Medicare Coverage — Every Scenario in One Place
All three pathways and the situations where none apply, with what you actually pay at each entry point.
| Coverage Scenario | Standard Part D? | Monthly Cost | Counts Toward $2,100 Cap? | Prior Auth? | Key Requirement |
|---|---|---|---|---|---|
| Zepbound for OSA (sleep apnea) | ✅ Yes | $200–$400 → $0 after cap | ✅ Yes | Required | G47.33 diagnosis · BMI ≥30 · Sleep study |
| Zepbound via GLP-1 Bridge (weight loss) | ⚡ Outside Part D | $50 flat/mo | ❌ No | Required | BMI ≥35, or ≥30/≥27 with qualifying conditions · KwikPen only |
| Zepbound for weight loss alone (no qualifying conditions) | ❌ Not covered | Full retail or LillyDirect $499 | ❌ No | N/A | Federal law prohibits coverage |
| Mounjaro (same ingredient, type 2 diabetes) | ✅ Yes | $200–$400 → $0 after cap | ✅ Yes | Required | Type 2 diabetes diagnosis (E11) · prior auth |
| Already on Part D GLP-1 for diabetes/OSA | ✅ Continues as-is | Plan cost-sharing | ✅ Yes | As required by plan | Not eligible for Bridge — continue standard Part D |
| Zepbound — Extra Help / LIS recipient (OSA) | ✅ Yes — reduced copay | Low flat copay (LIS rates apply) | ✅ Yes | Required | Same OSA criteria · LIS reduces cost-sharing |
| Zepbound — Extra Help recipient (Bridge) | ⚡ Outside Part D | $50 flat (LIS does NOT help) | ❌ No | Required | Extra Help does not reduce the $50 Bridge copay |
Zepbound vs. Mounjaro — Same Drug, Very Different Medicare Coverage
This is the single most consequential brand distinction in Medicare GLP-1 coverage. Both names mean tirzepatide. The box determines whether Medicare pays.
🔵 Zepbound (Tirzepatide)
- FDA approved: Weight management + sleep apnea
- Medicare Part D: Sleep apnea pathway (OSA)
- Medicare Bridge: $50/mo (KwikPen only)
- Weight loss alone: Not covered under Part D
- ICD-10: G47.33 (OSA) for Part D coverage
- Dosing: 2.5 mg to 15 mg weekly injection
🟢 Mounjaro (Tirzepatide)
- FDA approved: Type 2 diabetes management
- Medicare Part D: Covered for diabetes (standard)
- Medicare Bridge: Not applicable — Part D instead
- Weight loss: Not the approved indication (same effect)
- ICD-10: E11 (type 2 diabetes) for Part D coverage
- Dosing: Same 2.5 mg to 15 mg weekly injection
When we reviewed the coverage landscape for Medicare patients seeking tirzepatide, people with type 2 diabetes consistently end up with better coverage terms through Mounjaro under standard Part D. Mounjaro for diabetes uses standard Part D cost-sharing with the full $2,100 annual cap protection. Zepbound for the same patient through the Bridge involves a $50 monthly copay that doesn’t count toward the cap. If your primary medical condition is type 2 diabetes, ask your doctor to prescribe Mounjaro, not Zepbound — you’re getting the same molecule at terms that are almost always more financially favorable under Medicare. Switching between them just requires a new prescription.
Find Your Situation
Possibly on both counts — but you need the sleep study first. Zepbound became the first-ever FDA-approved medication for obstructive sleep apnea in December 2024. Before that, the only treatments were mechanical (CPAP, BiPAP, oral devices, or surgery). If you have obesity and your doctor suspects sleep apnea, the path is: get a referral for a home sleep test or in-lab sleep study, get the diagnosis confirmed, and then your doctor can submit a prior authorization for Zepbound under the sleep apnea indication. Medicare Part B generally covers sleep testing under diagnostic services. The coverage for Zepbound then goes through Part D with the standard cost-sharing structure. Do not self-diagnose or assume a Zepbound prescription will be covered before the sleep study confirms the diagnosis — the prior authorization process requires the confirmed sleep study documentation.
Check your BMI and health conditions against the GLP-1 Bridge eligibility tiers. If your BMI is 35 or above, you qualify for the Bridge without needing any additional diagnosis — $50 per month for Zepbound KwikPen through December 2027. If your BMI is between 27 and 34, you need one of the qualifying health conditions: prediabetes, a prior heart attack or stroke, heart failure, uncontrolled hypertension, chronic kidney disease, or symptomatic peripheral artery disease. If you don’t meet any of these criteria, standard Medicare Part D won’t cover Zepbound for weight loss alone. Your options at that point are LillyDirect ($499/month for single-dose vials, no insurance required), or asking your doctor whether compounded tirzepatide from a licensed 503B compounding pharmacy might be appropriate — though Medicare does not cover compounded medications.
This transition catches many people off guard. When you move from commercial insurance to Medicare, Zepbound coverage does not automatically transfer, and the coverage terms change significantly. If you were using Zepbound for weight loss on commercial insurance, Medicare won’t cover that under standard Part D. Your options are the Bridge (if you meet the BMI criteria) or the OSA pathway (if you also have sleep apnea). If you were using Zepbound for sleep apnea on commercial insurance, the Part D OSA pathway applies — but you’ll need a new prior authorization under your Medicare Part D plan, and a sleep study confirmation may be required again. Give yourself 60 to 90 days before your Medicare start date to explore which pathway applies and start the prior authorization process so there’s no gap in your medication supply.
First, get the denial explanation in writing. The denial reason determines the fix. If the denial says “not medically necessary” and you have confirmed OSA, the problem is almost certainly documentation — either the prior authorization didn’t include the sleep study results, used the wrong ICD-10 code, or didn’t document obesity (BMI 30+). Have your doctor resubmit the prior authorization with complete documentation: the sleep study report, the G47.33 diagnosis code, and your current BMI. If the denial says the drug is “not on formulary” for your plan, you can request a formulary exception — your doctor submits documentation of medical necessity and why no formulary alternative is appropriate. You have the right to appeal any denial. Contact your State Health Insurance Assistance Program (SHIP) for free help with appeals — these counselors specialize in exactly this type of coverage dispute.
For most Extra Help (Low Income Subsidy) recipients, the sleep apnea pathway is financially superior to the Bridge if you have a qualifying OSA diagnosis — because Extra Help reduces your Part D cost-sharing significantly, and those costs count toward the $2,100 cap. The Bridge does not give you any discount from $50, regardless of your income. If you do not have OSA and want Zepbound for weight loss, the Bridge at $50 per month is still meaningful access that didn’t exist before July — but go in knowing that your Extra Help benefit offers no additional relief on that $50 copay. For someone normally paying $5 to $10 per drug under Extra Help, the $50 Bridge copay is a significant jump.
Official Resources and Contacts
Medicare coverage rules for Zepbound confirmed against CMS official documentation for the Medicare GLP-1 Bridge program, FDA drug approval records (Zepbound OSA indication, December 20, 2024; weight management indication, November 2023), CMS Part D benefit parameters for 2026 (including the $615 deductible cap and $2,100 out-of-pocket maximum), and the ICD-10 coding guidance for obstructive sleep apnea (G47.33). Bridge program details — covered formulations, $50 copay, exclusion of the $50 from the out-of-pocket cap, Extra Help non-applicability, and Humana as central processor — are sourced from official CMS and Medicare Interactive documentation. The Mounjaro/Zepbound comparison reflects FDA approval records: Mounjaro (type 2 diabetes, May 2022), Zepbound (weight management, November 2023; OSA, December 2024). In our review of coverage denial patterns and prior authorization documentation, G47.33 coding and sleep study documentation were identified as the primary correctable causes of Part D OSA coverage denials. This page is independent and not affiliated with CMS, Medicare, Eli Lilly, or any insurance plan. Coverage rules and program terms can change — verify current formulary status at Medicare.gov before making coverage decisions.
Key sources: CMS.gov Medicare GLP-1 Bridge program documentation and FAQs; FDA drug approval records for tirzepatide; KFF Health News Medicare GLP-1 Bridge reporting (July 2026); Medicare Interactive (medicareinteractive.org) GLP-1 Bridge program guide; CMS 2026 Part D benefit parameters; AMA physician guidance on GLP-1 Bridge prescribing (June 2026).